These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 16971715

  • 1. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
    Massberg S, von Andrian UH.
    N Engl J Med; 2006 Sep 14; 355(11):1088-91. PubMed ID: 16971715
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Fingolimod for multiple sclerosis.
    Pelletier D, Hafler DA.
    N Engl J Med; 2012 Jan 26; 366(4):339-47. PubMed ID: 22276823
    [No Abstract] [Full Text] [Related]

  • 4. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
    Kowarik MC, Pellkofer HL, Cepok S, Korn T, Kümpfel T, Buck D, Hohlfeld R, Berthele A, Hemmer B.
    Neurology; 2011 Apr 05; 76(14):1214-21. PubMed ID: 21464424
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Fingolimod therapy for multiple sclerosis.
    Willis MA, Cohen JA.
    Semin Neurol; 2013 Feb 05; 33(1):37-44. PubMed ID: 23709211
    [Abstract] [Full Text] [Related]

  • 7. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
    Tar L, Vécsei L.
    Ideggyogy Sz; 2012 Mar 30; 65(3-4):83-100. PubMed ID: 23136726
    [Abstract] [Full Text] [Related]

  • 8. Fingolimod for relapsing multiple sclerosis: an update.
    Horga A, Castilló J, Montalban X.
    Expert Opin Pharmacother; 2010 May 30; 11(7):1183-96. PubMed ID: 20367536
    [Abstract] [Full Text] [Related]

  • 9. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
    Lee CW, Choi JW, Chun J.
    Arch Pharm Res; 2010 Oct 30; 33(10):1567-74. PubMed ID: 21052934
    [Abstract] [Full Text] [Related]

  • 10. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.
    Huggins A, Sergott RC.
    Curr Opin Ophthalmol; 2011 Nov 30; 22(6):447-50. PubMed ID: 21946305
    [No Abstract] [Full Text] [Related]

  • 11. [New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod].
    Komoly S.
    Ideggyogy Sz; 2012 Nov 30; 65(11-12):421-2. PubMed ID: 23289178
    [No Abstract] [Full Text] [Related]

  • 12. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):402-15. PubMed ID: 20089954
    [Abstract] [Full Text] [Related]

  • 13. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?
    Castrop F, Kowarik MC, Albrecht H, Krause M, Haslinger B, Zimmer C, Berthele A, Hemmer B.
    Neurology; 2012 Mar 20; 78(12):928-30. PubMed ID: 22402856
    [No Abstract] [Full Text] [Related]

  • 14. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
    [Abstract] [Full Text] [Related]

  • 15. Effects of fingolimod in relapsing-remitting multiple sclerosis.
    Sorensen PS.
    Lancet Neurol; 2014 Jun 04; 13(6):526-7. PubMed ID: 24685277
    [No Abstract] [Full Text] [Related]

  • 16. [Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
    García-Merino JA, Sánchez AJ.
    Rev Neurol; 2012 Jul 01; 55(1):31-7. PubMed ID: 22718407
    [Abstract] [Full Text] [Related]

  • 17. Oral therapy for multiple sclerosis--sea change or incremental step?
    Carroll WM.
    N Engl J Med; 2010 Feb 04; 362(5):456-8. PubMed ID: 20089958
    [No Abstract] [Full Text] [Related]

  • 18. The utility of pharmacokinetic-pharmacodynamic modeling in the discovery and optimization of selective S1P(1) agonists.
    Taylor S, Gray JR, Willis R, Deeks N, Haynes A, Campbell C, Gaskin P, Leavens K, Demont E, Dowell S, Cryan J, Morse M, Patel A, Garden H, Witherington J.
    Xenobiotica; 2012 Jul 04; 42(7):671-86. PubMed ID: 22225501
    [Abstract] [Full Text] [Related]

  • 19. Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis.
    Johnson TA, Lapierre Y, Bar-Or A, Antel JP.
    Arch Neurol; 2010 Dec 04; 67(12):1449-55. PubMed ID: 21149809
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.